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Abstract
Key questions remain unresolved regarding the advantages and limitations of colloids for
fluid resuscitation despite extensive investigation. Elucidation of these questions has been
slowed, in part, by uncertainty as to the optimal endpoints that should be monitored in
assessing patient response to administered fluid. Colloids and crystalloids do not appear to
differ notably in their effects on preload recruitable stroke volume or oxygen delivery. Limited
evidence nevertheless suggests that colloids might promote greater oxygen consumption
than crystalloids. It remains unclear, in any case, to what extent such physiological
parameters might be related to clinically relevant outcomes such as morbidity and mortality.
Recent randomized controlled trial results indicate that, at least in certain forms of fluid
imbalance, albumin is effective in significantly reducing morbidity and mortality. Much further
investigation is needed, however, to determine the effects of colloid administration on
clinically relevant outcomes in a broad range of critically ill patients. The ability of
administered colloids to increase colloid osmotic pressure (COP) constitutes one
mechanism by which colloids might reduce interstitial oedema and promote favourable
patient outcomes. However, the applicability of this mechanism may be limited, due to the
operation of compensatory mechanisms such as increased lymphatic drainage. Attempts to
increase COP might also be less useful in states of increased vascular permeability such as
acute respiratory distress syndrome, although this issue has by no means been settled by
empirical data. Colloids are clearly more efficient than crystalloids in attaining resuscitation
endpoints as judged by the need for administration of far smaller fluid volumes. Among the
colloids, albumin offers several advantages compared with artificial colloids, including less
restrictive dose limitations, lower risk of impaired haemostasis, absence of tissue deposition
leading to severe prolonged pruritus, reduced incidence of anaphylactoid reactions, and
ease of monitoring to prevent fluid overload. The cost of albumin, nevertheless, limits its
usage. Crystalloids currently serve as the first-line fluids in hypovolaemic patients. Colloids
can be considered in patients with severe or acute shock or hypovolaemia resulting from
sudden plasma loss. Colloids may be combined with crystalloids to obviate administration of
large crystalloid volumes. Further clinical trials are needed to define the optimal role for
colloids in critically ill patients.
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ARDS = acute respiratory distress syndrome; COP = colloid osmotic pressure; LVSWI = left ventricular stroke work index; PaO2/FiO2 = ratio
between the fraction of inspired oxygen and the partial pressure of oxygen in arterial blood; PAWP = pulmonary artery wedge pressure; RCT =
randomized controlled trial.
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Introduction
The long-standing controversy regarding the optimal role
of colloids in fluid resuscitation shows little sign of
abating. Indeed, two recent meta-analyses have reintensi-
fied the debate [1,2]. Although investigations related to
this issue have spanned four decades, many questions
remain unresolved. Yet this area of clinical investigation
remains highly active, and some of the most recent data
on potential advantages of colloid administration have pro-
vided important new insight [3].
Given the continuing accumulation of relevant clinical
data, it is pertinent to ask what conclusions can now be
drawn regarding the appropriate role of both natural and
artificial colloids. What are the most useful endpoints for
evaluating the effects of administered fluids? From the
clinical standpoint, how important is COP? How similar
are natural and artificial colloids in their properties? Is
there conclusive evidence of differences in patient out-
comes with colloids versus crystalloids? In what clinical
situations might colloids offer advantages over crystal-
loids? These are the primary issues that this review is
intended to address.
Fluid resuscitation endpoints
Hypovolaemia is very difficult to detect at the bedside [4].
Neither hypotension nor severe tachycardia may be appar-
ent. Stroke volume may be declining; however, this decline
may go undetected unless measurements are made of this
parameter. What, then, is the optimal set of fluid resuscita-
tion endpoints that should be monitored to promote
favourable patient outcomes? The definitive answer is not
yet at hand. Oliguria, generally regarded as an adverse
finding, might in one scenario prompt the administration of
fluid. As a result, increases might be achieved in blood
pressure, oxygen delivery to the tissues and, perhaps,
associated oxygen consumption. These changes may be
associated with increased preload recruitable stroke work,
resulting in decreased lactate levels. The tonometric PCO2
gradient could also provide a useful measure of regional
perfusion adequacy. It is nevertheless unclear whether this
would be the optimal parameter to monitor, either alone or
in conjunction with other measurements. The type of fluid
that would be of greatest utility in rectifying the patient’s
oliguria is also unclear.
In a randomized controlled trial (RCT) of 26 patients with
hypovolaemic and septic shock, the left ventricular stroke
work index (LVSWI) was found to rise with increasing pul-
monary artery wedge pressure (PAWP) following fluid chal-
lenge [5]. This finding provides evidence for the existence
of preload recruitable stroke work in hypovolaemia. The
volume of crystalloid needed to maintain the target PAWP
level was two- to four-fold greater than that of colloid.
Increased LVSWI is associated with rising PAWP up to
approximately 12mmHg whereas, at PAWP>12mmHg,
little or no further rise is observed in LVSWI [6]. Colloids
and crystalloids have not been found to differ notably in
promoting a preload recruitable stroke work response.
Choice of fluid, however, may affect oxygen delivery and
associated oxygen consumption, although relevant data
are scanty. Infusion of Ringer’s lactate in hypovolaemic
surgical patients resulted in modest oxygen delivery
increases due to greater preload recruitable stroke work,
but concomitant augmentation of oxygen consumption
was not observed [7]. In patients receiving 25% albumin,
by contrast, the magnitude of increase in oxygen delivery
was significantly greater than that of Ringer’s lactate
recipients, and albumin infusion was also associated
with rising oxygen consumption. The precise mecha-
nisms and consequences of these phenomena have yet
to be delineated. It is plausible that Ringer’s lactate may
increase tissue oedema as compared with hyperoncotic
albumin. The expected effect of such oedema would be
to retard oxygen uptake by increasing distances from the
blood vessels to the mitochondria. In this regard, natural
colloid may exert more favourable effects on tissue
oxygenation than a crystalloid. The extent to which such
fluid-associated differences in oxygenation might
translate into morbidity or mortality differences remains
to be defined. Further studies are needed to confirm the
relationship between fluid type and oxygenation, and to
characterize this relationship in terms of clinically
relevant outcomes.
One recently reported RCT of patients with cirrhosis and
spontaneous bacterial peritonitis has demonstrated supe-
rior outcomes in terms of both morbidity and mortality in
patients receiving albumin [3]. Such patients experience
circulatory dysfunction characterized by vasodilatation,
hypotension, elevated cardiac output, diminished effective
blood volume, activation of the renin–angiotensin and
sympathetic nervous systems, and increased circulating
arginine vasopressin and endothelin. Volume expansion
with albumin might avert this circulatory dysfunction by
maintaining effective blood volume and prevent subse-
quent renal impairment. The frequency of renal impair-
ment, as shown in Figure 1, was significantly lower in
albumin recipients than in the control group, and mortality
was significantly reduced both during hospitalization and
at 3 months after discharge.
Colloid osmotic pressure
Based upon Starling’s equation, COP should theoretically
be important for maintaining fluid balance in patients by
virtue of its influence on fluid flux between the intravascular
and extravascular compartments. Depressed COP during
hypovolaemia could contribute to interstitial fluid overload
and oedema formation. Impaired blood flow, oxygen trans-
port, and hepatic and renal function might result. Oedema
in the lungs would lead to deterioration in gas exchange.The role played by COP may nevertheless not be major.
Low plasma COP, for example, may not result in tissue
oedema under normal circumstances due to compen-
satory mechanisms such as increased lymphatic drainage.
Attempts in increased permeability states to increase
COP by administration of colloids could also fail to amelio-
rate interstitial oedema. The normal transcapillary escape
rate of albumin, mediated in major part by the liver, is
5%/h. Fluid filtration, surface area and permeability are the
primary factors affecting transcapillary escape rate, and
clinical conditions associated with an elevation of this rate
are summarized in Table 1.
In acute respiratory distress syndrome (ARDS) and associ-
ated conditions, for example, COP may be of limited impor-
tance as a determinant of tissue hydration status. Pulmonary
oedema may thus be more dependent on hydrostatic forces
than on COP. Differential effects of colloids and crystalloids
on fluid balance and oedema formation may consequently
not be operative in ARDS. Such differential effects may,
however, assume importance in particular time intervals
during the course of certain critical illnesses.
If increasing COP is deemed clinically desirable, it can be
accomplished by administration of either natural or artifi-
cial colloid. In hypovolaemic postoperative patients, for
example, either albumin or hetastarch administration
resulted in sustained COP increases [8]. Saline
decreased COP. Albumin and hetastarch were found
effective in patients with hypovolaemic and septic shock,
both in raising COP and maintaining the COP–PAWP
gradient, whereas saline conversely decreased COP and
markedly reduced the COP–PAWP gradient [5]. A
decreased COP–PAWP gradient in a study of 76 critically
ill patients was associated with the occurrence and sever-
ity of pulmonary oedema and, in the subset of patients
with circulatory shock, was also predictive of mortality [9].
In light of these observations, might the choice of resus-
citation fluid influence pulmonary oedema formation?
Available evidence bearing on this issue is highly limited.
COP declined substantially in patients receiving Ringer’s
lactate but not 5% plasma protein fraction in a prospec-
tive study of 18 patients undergoing aortic reconstruc-
tive surgery. No corresponding difference could be
demonstrated in extravascular lung water, however, as
directly measured by a thermal green dye double indica-
tor dilution technique [10]. This lack of difference might
be attributable to a compensatory increase in lymphatic
flow among the Ringer’s lactate recipients.
Pulmonary oedema was indirectly assessed by alveolar to
arterial oxygen gradient and intrapulmonary shunt in a RCT
of 141 patients undergoing laparotomy for acute abdomi-
nal trauma [11]. Neither parameter differed significantly
over the 5-day study observation period between patients
receiving 4% albumin versus Ringer’s lactate. The inci-
dence of radiographically demonstrable pulmonary oedema
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Figure 1
Percent incidence of kidney impairment and death in albumin
recipients and control patients with cirrhosis and spontaneous
bacterial peritonitis. Based on the data of Sort et al [3].
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Table 1
Clinical conditions associated with increased albumin
transvascular escape rate
Hypertension
Congestive heart failure
Exercise
Catecholamines
Diabetes mellitus
Infection, sepsis and shock
Hypothyroidism
Major surgery and trauma
Fluid loading
Chemotherapy
Vasculitis and glomerulonephritis
Cardiopulmonary bypass
Ischaemia/reperfusion
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in another RCT was, however, significantly higher in
patients receiving saline than either albumin or hetastarch
[5]. Fluid overload with colloid may, on the other hand,
impair respiratory function as evaluated by the ratio
between the fraction of inspired oxygen and the partial
pressure of oxygen in arterial blood (PaO2/FiO2) [12].
Albumin versus artificial colloids
Artificial colloids such as hetastarch have been extensively
investigated as alternatives to albumin. Although artificial
colloids typically provide volume expansion comparable
with that of albumin, they are nevertheless subject to
certain disadvantages. For example, limitations in recom-
mended doses may be exceeded in some patients, so that
albumin may be required to meet the further fluid needs of
the patient. Although available evidence is conflicting, het-
astarch may be associated with impaired haemostasis
[13]. Deposition of hetastarch in the skin can frequently
lead to severe protracted pruritus [14]. Impaired renal
function has also been documented in association with
hetastarch usage [15]. Finally, the incidence of anaphylac-
toid reactions may be higher in hetastarch than albumin
recipients [16].
In view of the potential deleterious effects that might result
from colloid overload, as already indicated, one advantage
of albumin vis-à-vis artificial colloids is the reduced likeli-
hood of administering excessive fluid. COP is seldom
measured on a routine basis. Overload with artificial col-
loids is hence not readily detected, and dose-dependent
side effects may be difficult to avoid. Albumin concentra-
tion, in contrast, is a routine daily laboratory determination.
Furthermore, more frequent albumin assays can be per-
formed during resuscitation, and such monitoring can
serve to prevent overtreatment with albumin.
Discussion
Two recent meta-analyses have raised questions regarding
the safety of both albumin specifically [2] and colloids gen-
erally [1]. Mortality was adopted as the endpoint of these
meta-analyses based upon RCTs involving various critical ill-
nesses and fluid regimens. There was nevertheless no sta-
tistically significant difference in mortality between
hypovolaemic patients in the albumin and control groups
[2]. Similarly, mortality did not differ significantly between
the colloid and control groups in RCTs involving trauma,
surgery, burns and other indications [1]. Thus, neither meta-
analysis provides convincing evidence that resuscitation is
more hazardous with a colloid than a crystalloid. Further-
more, the RCTs included in both meta-analyses were strik-
ingly heterogeneous with respect to indications for fluid
administration, patient population, and resuscitation
regimen. No attempt was made to exclude RCTs involving
obvious colloid overload, which would be expected to
contribute to adverse outcomes. Some unpublished data
were included. The meta-analyses, importantly, also did not
adequately address plausible mechanisms upon which
potential mortality differences might be based. It is conse-
quently difficult to draw unequivocal inferences from the
meta-analyses.
Colloids are clearly more efficient than crystalloids in attain-
ing resuscitation endpoints, since much less fluid volume is
required. The Starling equation provides a theoretical basis
for the expectation that colloids will be less likely than crys-
talloids to contribute to interstitial oedema and deleterious
sequelae thereof. The clinical significance of this theoreti-
cal difference in the properties of resuscitation fluids never-
theless remains to be established. Although recent data in
cirrhosis patients suggest that albumin may, at least in
certain clinical settings, reduce morbidity and mortality,
present evidence supporting the ability of albumin or other
colloids to improve such clinical outcomes in a broad range
of patients is inadequate and inconclusive.
Albumin remains the standard of comparison for colloids,
and this natural colloid offers certain advantages over arti-
ficial alternatives. The cost of albumin, however, places
limitations on its use.
What approaches to fluid management are appropriate in
light of the evidence reviewed? Crystalloids are clearly
suitable as first-line fluids in the hypovolaemic patient. Col-
loids can be considered in cases of severe or acute shock
or hypovolaemia resulting from sudden plasma loss. A
combined regimen of crystalloid and colloid may also be
useful for patients who might require large volumes of
crystalloid alone.
Current understanding of the advantages and limitations
associated with different resuscitation fluids remains far
from complete. Further studies are needed to address
the unresolved issues in fluid management. For instance,
some useful answers might be furnished by further clini-
cal trials comparing crystalloids with natural and artificial
colloids with respect to pulmonary side effects such as
fluid accumulation and permeability, as measured using
radiolabelled proteins or albumin, following a given
intravascular fluid challenge to a target PAWP.
Conclusion
Crystalloids are appropriate as first-line resuscitation fluid
in patients with hypovolaemia. Colloids may be consid-
ered in patients with severe or acute shock or hypo-
volaemia due to sudden plasma loss. It may be useful,
since the volume of crystalloid needed to achieve resusci-
tation endpoints exceeds that of colloid by two- to three-
fold, to combine a colloid with a crystalloid in the fluid
management regimen of patients who might require large
volumes of crystalloid alone. Further studies are needed
to define the comparative merits of particular resuscita-
tion fluids.Critical Care    Vol 4 Suppl 2 Groeneveld
Commentary
Jean-Louis Vincent, MD, PhD: What are the patient popu-
lations that might be enrolled in clinical trials of respiratory
function in relation to resuscitation fluid?
AB Johan Groeneveld, MD: Patients with established
ARDS and others with risk factors for ARDS such as
sepsis, trauma, or surgery. Membrane permeability will be
increased in the cases of established ARDS, and differ-
ences between colloids and crystalloids may not be
demonstrable in this indication, although there is the pos-
sibility that some types of artificial colloids might exert a
sealant effect on the membranes.
Uwe Kreimeier, MD: The distinct properties of particular
colloids such as albumin, dextran, hetastarch, and gelatin
are well recognized. It may also be important to differenti-
ate between particular crystalloids, for example with
respect to effects on pH. In a recent study, rapid infusion
of 0.9% saline but not Ringer’s lactate resulted in hyper-
chloraemic acidosis among patients undergoing gynaeco-
logic surgery [17]. So particularly if large volumes of
crystalloid are to be infused, it is important to be aware of
the potential of particular crystalloids to alter blood pH
and possibly cause severe perturbations in blood flow.
Andrew R Webb, MD: Although COP is not routinely
measured in most critical care settings, these measure-
ments can be quite important in patients with renal failure
on artificial renal support who are receiving artificial col-
loids, particularly hydroxyethyl starches. In that group of
patients COP can become elevated, impairing glomerular
filtration and prolonging the renal failure.
William J Sibbald, MD: At our institution, a RCT has been
recently completed comparing pentastarch and albumin in
cardiopulmonary bypass patients. The presumption was
that the two fluids would prove equivalent. Indeed, with
respect to nearly all postoperative endpoints, there were
no significant between-group differences. However, the
patients receiving pentastarch required on average 1.2
units more blood, even though no measurable coagulation
defect was observed. The difference in blood requirement
convinced our cardiac surgeons that albumin should
remain the fluid of choice in these patients.
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